Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin. Infect. Dis

The efficacy of vancomycin in the treat-ment of infections due to methicillin-resistant Staphylococcus aureus (MRSA) was debated at the 2006 annual meeting of the Infectious Diseases Society of America (IDSA) [1, 2]. This encounter was engendered by an increasing number of reports of failure of vancomycin therapy in patients with serious infections due to MRSA, together with the results of in vitro and pharmacodynamic studies. Among the latter were the observation by some groups of ‘‘minimum inhibitory concen-tration creep’ ’ and the recognition that the then-standard dosing of vancomycin wa